BioBusiness and Innovation Program

Dear KU Master and PhD Students,

The BioBusiness and Innovation Program and The Boston Consulting Group invite master and PhD students from DTU, KU and CBS to a joint information meeting and networking event.

 

Professionals capable of bridging technical issues and management are in increasing demand from the biotech industry in Denmark.

 

We are proud to introduce the first joint course offered jointly by Copenhagen Business School (CBS), The Technical University of Denmark (DTU) and The University of Copenhagen (KU); BioBusiness & Innovation Program, BBIP.

 

The course combines competencies from top students from the three institutions, taking them through all the different steps in developing a successful biotech business; from idea generation to a product ready to commercialize.

 

The course covers issues in entrepreneurship and biotech with lecturers from some of the most successful Danish biotech companies, among these Novozymes, LEO Pharma, Høiberg, Novo, and The Boston Consulting Group. Participation in the program gives 7,5 ECTS.

 

We believe that this program could be of interest to you, and we therefore invite you to an information meeting where we, in collaboration with The Boston Consulting group, will provide you with further details on the program.

 

When: Thursday, May 5th, 2011 4:00 PM – 5:30 PM

Where: Copenhagen Business School Building: Kilen, Kilevej 14A DK - 2000 Frederiksberg Room: Ks48 (ground floor)

 

16:00 – 16:30 BBIP introduction and application process

By Finn Valentin, Professor, Copenhagen Business School, BBIP advisory board member

16:30 – 17:00 BCG and BBIP – Innovation to Cash

By The Boston Consulting Group

17:00 – 17:15 BBIP alumni sharing experiences

By Henriette Kirkegaard (CBS), Christian Schrøder Kaas (KU LIFE) and Sara Holm Christiansen (DTU)

17:15 – Buffet and networking

Registration Are you interested in attending this event, please RSVP no later than May 3rd, 2011 to .

 

We are very much looking forward to seeing you!

 

Best regards,

The BioBusiness and Innovation Program and The Boston Consulting Group